News and Information
Recent News
March 15, 2009, Press Release
Phylonix Granted Broad U.S. Patent for Assessing Cardiac Functions in Zebrafish
Phylonix Pharmaceuticals announced, at the Society of Toxicology Annual Meeting beginning today in Baltimore, that the U.S. Patent and Trademark Office has issued the company a broad patent for assessing the toxicity of pharmaceutical test agents on cardiovascular functions in zebrafish. U.S. Patent No. 7,482,507, “Methods for Screening Agents for Activity Using Teleosts,” which has 22 claims, includes assessment of heart rate in zebrafish and use of microplates for high-throughput screening. Read Article
January 7, 2009, Press Release
NIH Grants Phylonix Phase II SBIR to Develop High-Throughput In vivo Zebrafish Assays for Assessing Cytochrome P450 Drug Metabolism and Safety
Phylonix Pharmaceuticals, Inc. today announced that it has been awarded a $1,250,369 Phase II Small Business Innovation Research Grant (SBIR) from the National Institute of General Medical Sciences of the National Institutes of Health (NIH) to develop in vivo zebrafish assays for assessing drug effects on Cytochrome (CYP) P450s. CYP profiling, a critical step in drug development, is required by the Food and Drug Administration (FDA) for all new drug approvals. Read Article
<<Back to Home Page